Abstract
Imatinib, a targeted inhibitor of the tyrosine kinase activity of the BCR-ABL oncoprotein, has demonstrated considerable efficacy in all phases of chronic myeloid leukemia (CML). [1][1] Recently, Palandri and colleagues reported on the long-term outcomes of patients with CML in accelerated phase[2][